<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>828</ReferenceId>
        <DateLastUpdated>2020-09-10-07:00</DateLastUpdated>
        <Article>
            <PubmedId>11544317</PubmedId>
            <Abstract>Because little is known about lymphocyte responses in the nasal mucosa, lymphocyte accumulation in the nasal mucosa, nasal-associated lymphoid tissue (NALT), and cervical lymph nodes (CLN) were determined after primary and heterosubtypic intranasal influenza challenge of mice. T cell accumulation peaked in the nasal mucosa on day 7, but peaked slightly earlier in the CLN (day 5) and later (day 10) in the NALT. Tetrameric staining of nasal mucosal cells revealed a peak accumulation of CD8 T cells specific for either the H-2D(b) influenza nucleoprotein epitope 366-374 (D(b)NP(366)) or the H-2D(b) polymerase 2 protein epitope 224-233 (D(b)PA(224)) at 7 days. By day 13, D(b)PA(224)-specific CD8 T cells were undetectable in the mucosa, whereas D(b)NP(366)-specific CD8 T cells persisted for at least 35 days in the mucosa and spleen. After heterosubtypic virus challenge, the accumulation of CD8 T cells in the nasal mucosa was quicker, more intense, and predominantly D(b)NP(366) specific relative to the primary inoculation. The kinetics and specificity of the CD8 T cell response were similar to those in the CLN, but the responses in the NALT and spleen were again slower and more protracted. These results indicate that similar to what was reported in the lung, D(b)NP(366)-specific CD8 T cells persist in the nasal mucosa after primary influenza infection and predominate in an intensified nasal mucosal response to heterosubtypic challenge. In addition, differences in the kinetics of the CD8 T cell responses in the CLN, NALT, and spleen suggest different roles of these lymphoid tissues in the mucosal response.</Abstract>
            <ArticleYear>2001</ArticleYear>
            <ArticlePages>3293-9</ArticlePages>
            <ArticleTitle>Antigen-specific CD8(+) T cells persist in the upper respiratory tract following influenza virus infection.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Wiley</LastName>
                    <ForeName>J A</ForeName>
                </Author>
                <Author>
                    <LastName>Hogan</LastName>
                    <ForeName>R J</ForeName>
                </Author>
                <Author>
                    <LastName>Woodland</LastName>
                    <ForeName>D L</ForeName>
                </Author>
                <Author>
                    <LastName>Harmsen</LastName>
                    <ForeName>A G</ForeName>
                </Author>
            </Authors>
            <Affiliations>Trudeau Institute, Saranac Lake, NY 12983, USA. jwiley@trudeauinstitute.org.</Affiliations>
            <ArticleChemicalList>Aerosols;Antigens, Viral;H-2 Antigens;Histocompatibility Antigen H-2D;Influenza Vaccines;PB2 protein, Influenzavirus A;Peptide Fragments;Viral Core Proteins;Viral Proteins;nucleoprotein (366-374), influenza virus;RNA Replicase</ArticleChemicalList>
            <ArticleMeshHeadingsList>Administration, Intranasal; Aerosols; Animals; Antigens, Viral(immunology); CD4-Positive T-Lymphocytes(immunology); CD8-Positive T-Lymphocytes(immunology); Epithelium(immunology; virology); Female; H-2 Antigens(immunology); Histocompatibility Antigen H-2D; Immunization; Influenza A virus(immunology; isolation &amp; purification); Influenza Vaccines(administration &amp; dosage; immunology); Kinetics; Lymph Nodes(immunology; pathology); Male; Mice; Mice, Inbred C57BL; Nasal Mucosa(immunology; pathology); Neck; Organ Specificity; Orthomyxoviridae Infections(immunology; pathology; virology); Peptide Fragments(immunology); RNA Replicase; T-Lymphocytes, Cytotoxic(immunology); Time Factors; Viral Core Proteins(immunology); Viral Proteins(immunology)</ArticleMeshHeadingsList>
            <Journal>
                <Volume>167</Volume>
                <Issue>6</Issue>
                <Title>Journal of immunology (Baltimore, Md. : 1950)</Title>
                <Issn>0022-1767</Issn>
                <MedlineTa>J Immunol</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>NP 366-374</EpitopeName>
                <EpitopeStructure>
                    <SequenceMoleculeNoNaturalSource>
                        <ChemicalType>Peptide, no natural source</ChemicalType>
                        <LinearSequence>ASNENMETH</LinearSequence>
                    </SequenceMoleculeNoNaturalSource>
                </EpitopeStructure>
                <EpitopeRelatedObject>
                    <RelatedObjectType>The epitope is an analog of:</RelatedObjectType>
                    <RelatedObject>
                        <FragmentOfANaturalSequenceMolecule>
                            <ChemicalType>Peptide from protein</ChemicalType>
                            <LinearSequence>ASNENMETM</LinearSequence>
                            <StartingPosition>366</StartingPosition>
                            <EndingPosition>374</EndingPosition>
                            <SourceMolecule>
                                <IedbAccession>SRC124</IedbAccession>
                            </SourceMolecule>
                            <SourceOrganismId>211044</SourceOrganismId>
                        </FragmentOfANaturalSequenceMolecule>
                    </RelatedObject>
                </EpitopeRelatedObject>
                <LocationOfData>Materials and methods</LocationOfData>
                <EpitopeId>4598</EpitopeId>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>Epitope NP ASNENMETH is an analog of peptide ASNENMETM from the nucleoprotein of influenza A virus (A/PR/8/34).</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 3</LocationOfData>
                        <TCellId>1007734</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                                <Age>6-8 weeks</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <DiseaseState>DOID:8469</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Other</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>132504</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Influenza A  X31</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intranasal</Route>
                                <DoseSchedule>Two</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>35 days after the initial intranasal infection with influenza A/X31, mice received intranasal influenza A/PR/8 virus.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <MhcAllele>
                            <MhcAlleleId>172</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>NP 366-374</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <SequenceMoleculeNoNaturalSource>
                                        <ChemicalType>Peptide, no natural source</ChemicalType>
                                        <LinearSequence>ASNENMETH</LinearSequence>
                                    </SequenceMoleculeNoNaturalSource>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>47</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Epitope specific CD8+ T cells increased after intranasal infection with influenza A X31 with a peak occurring at day 7 in the nasal mucosa, nasal-associated lymphoid tissue, cervical lymph nodes, and spleen. Subsequent challenge with intranasal influenza A/PR/8 virus resulted in a greater and quicker increase in epitope specific cells. A similar pattern of reactivity was seen with the influenza epitope PA 224-233, but with much lower numbers of specific cells in all tissues at all time points.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>PA 224-233</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>SSLENFRAYV</LinearSequence>
                        <StartingPosition>224</StartingPosition>
                        <EndingPosition>233</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>BAA99401.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>132504</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Materials and methods</LocationOfData>
                <EpitopeId>61151</EpitopeId>
                <ReferenceStartingPosition>224</ReferenceStartingPosition>
                <ReferenceEndingPosition>233</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 3</LocationOfData>
                        <TCellId>1007736</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                                <Age>6-8 weeks</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <DiseaseState>DOID:8469</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>132504</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Influenza A virus (A/X-31(H3N2))</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intranasal</Route>
                                <DoseSchedule>Two</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>35 days after the initial intranasal infection with influenza A/X31, mice received intranasal influenza A/PR/8 virus.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <MhcAllele>
                            <MhcAlleleId>172</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>PA 224-233</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>SSLENFRAYV</LinearSequence>
                                        <StartingPosition>224</StartingPosition>
                                        <EndingPosition>233</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>BAA99401.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>132504</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>47</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Epitope specific CD8+ T cells increased in the nasal mucosa after intranasal infection with influenza A X31 with a peak occurring at day 7. Subsequent challenge with intranasal influenza A/PR/8 virus resulted in a greater and quicker increase in epitope specific cells. A similar pattern was seen in the nasal-associated lymphoid tissue, cervical lymph nodes, and spleen, but with much lower numbers of epitope specific cells present. In all tissues and time points, more cells specific for the immunodominant influenza epitope, NP 366-374 were observed.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

